A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
Eli Lilly and Company
Compass Therapeutics
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Erasca, Inc.
Novartis
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Mayo Clinic
Shenzhen Ionova Life Sciences Co., Ltd.
Imugene Limited
Tizona Therapeutics, Inc
University of Iowa
Werewolf Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC
Riboscience, LLC.
Sairopa B.V.
Akamis Bio
Jazz Pharmaceuticals
InSilico Medicine Hong Kong Limited
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Erasca, Inc.
University of Chicago
Hummingbird Bioscience
TuHURA Biosciences, Inc.
Erasca, Inc.
Nectin Therapeutics Ltd
Incyte Corporation
Leap Therapeutics, Inc.
ALX Oncology Inc.
Trishula Therapeutics, Inc.
Acepodia Biotech, Inc.
invoX Pharma Limited
M.D. Anderson Cancer Center
Astellas Pharma Inc
Carisma Therapeutics Inc
Genentech, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Eli Lilly and Company
University of California, San Francisco
Wellmarker Bio
OHSU Knight Cancer Institute
Rutgers, The State University of New Jersey